In vivo estimates of efficacy at 5-HT1(A) receptors: Effects of EEDQ on the ability of agonists to produce lower-lip retraction in rats

Psychopharmacology

Volumn 149, Issue 4, 2000, Pages 377-387

  Koek, Wouter ^a   Assié, Marie Bernadette ^a   Zernig, Gerald ^b   France, Charles P ^c  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

5 HT1(A) agonist; Efficacy; Intrinsic activity; Irreversible antagonism; Lower lip retraction; Rat

Indexed keywords

SEROTONIN 1A AGONIST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DEPRESSION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0034079628     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130000374     Document Type: Article

References (53)

1. Arborelius L, Chergui K, Murase S, Nomikos GG, Hook BB, Chouvet G, Hacksell U, Svensson TH (1993) The 5-HT1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons. Naunyn Schmiedeberg's Arch Pharmacol 347:353-362
2. Arunlakshana O, Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol 14:48-58
3. 1A receptors. 8th International Conference on in vivo methods: Monitoring Molecules in Neuroscience
4. Bagdy G, To CT (1997) Comparison of relative potencies of i.v. and i.c.v. administered 8-OH-DPAT gives evidence of different sites of action for hypothermia, lower lip retraction and tail flicks. Eur J Pharmacol 323:53-58
5. 1A receptors induces lower lip retraction in the rat. Pharmacol Biochem Behav 33:821-827
6. Berendsen HHG, Broekkamp CLE, Van Delft AML (1991) Depletion of brain serotonin differentially affects behaviors induced by 5HT1A, 5HT1C, and 5HT2 receptor activation in rats. Behav Neural Biol 55:214-226
7. Berendsen HHG, Bourgondien FGM, Broekkamp CLE (1994) Role of dorsal and medial raphe nuclei in lower lip retraction in rats. Eur J Pharmacol 263:315-318
8. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, Clarke WP (1998) Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54:94-104
9. Black JW, Leff P (1983) Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 220:141-162
10. Black JW, Leff P, Shankley NP, Wood J (1985) An operational model of pharmacological antagonism: the effect of E/[A] curve shape on agonist dissociation constant estimation. Br J Pharmacol 84:561-571
11. 1A agonist with exceptional anxiolytic potential. Drug Dev Res 26:21-48
12. 1A receptor agonists: recent developments and controversial issues. Psychopharmacology 121:1-26
13. 1A receptors in psychopathology and the mechanism of action of clinically effective therapeutic agents. Drug News Perspect 9:270-280
14. 1A agonists in anxiety and depression. J Psychopharmacol 7:283-289
15. De Léan A, Munson PJ, Rodbard D (1978) Simultaneous analysis of families of sigmoidal curves: application to bioassay, radio-ligand assay, and physiological dose-response curves. Am J Physiol 235:E97-E102
16. Dourish CT, Hutson PH, Curzon G (1986) Para-chlorophenylalanine prevents feeding induced by the serotonin agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT). Psychopharmacology 89:467-471
17. 1A receptor antagonist, WAY-100635. Eur J Pharmacol 281:81-88
18. Fulton B, Brogden RN (1997) Buspirone. An updated review of its clinical pharmacology and therapeutic applications. CNS Drugs 7:68-88
19. Furchgott RF (1966) The use of beta-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. Adv Drug Res 3:21-56
20. Gozlan H, Laporte A-M, Thibault S, Schechter LE, Bolaños F, Hamon M (1994) Differential effects of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) on various 5-HT receptor binding sites in the rat brain. Neuropharmacology 33:423-431
21. 1 dopamine receptors and effector moieties by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo and in vitro. Mol Pharmacol 31:50-57
22. Hoyer D, Boddeke HWGM (1993) Partial agonists, full agonists, antagonists: dilemmas of definition. Trends Pharmacol Sci 14:270-275
23. 1A receptor turnover following irreversible blockade with EEDQ. Neuroreport 7:2717-2721
24. Keck BJ, Lakoski JM (1997) N-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) administration for studies of 5-HT(1A) receptor binding site inactivation and turnover. Brain Res Protocol 1:364-370
25. Kenakin T (1995) Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci 16:232-238
26. Kenakin T (1997) Pharmacologic analysis of drug-receptor interaction, 3rd edn. Raven Press, New York
27. Kenakin T (1999) Efficacy in drug receptor theory: outdated concept or under-valued tool? Trends Pharmacol Sci 20:400-405
28. Kleven MS, Koek W (1998) Discriminative stimulus effects of 8-hydroxy-2-(di-n-propylamino)tetralin in pigeons and rats: species similarities and differences. J Pharmacol Exp Ther 284: 238-249
29. 1A receptors in ethanol dependence. Eur J Pharmacol 281:219-228
30. 2 A/2C antagonist anxiolytics. II. Drug discrimination and behavioral observation studies in rats. J Pharmacol Exp Ther 282:747-759
31. 1A receptor agonist with marked anxiolytic and antidepressant potential. J Pharmacol Exp Ther 287:266-283
32. Leff P, Scaramellini C, Law C, McKechnie K (1997) A three-state model of agonist action. Trends Pharmacol Sci 18:355-362
33. 35S]GTPgammaS binding study. Eur J Pharmacol 355: 245-256
34. 1A receptor agonists in recombinant cell lines - modulation of apparent efficacy by G-protein activation state. Naunyn Schmiedeberg's Arch Pharmacol 356:551-561
35. Piñeyro G, Blier P (1999) Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol Rev 51:533-591
36. Pinto W, Battaglia G (1993) In vivo EEDQ dose-dependently inactivates rat brain 5-HT receptors but not 5-HT uptake sites. Neuroreport 5:61-64
37. 2-values by Schild-plot analysis and detection of allosteric interactions. Br J Pharmacol 106:710-716
38. Protais P, Chagraoui A, Arbaoui J, Mocaër E (1994) Dopamine receptor antagonist properties of S 14506, 8-OH-DPAT, raclo-pride and clozapine in rodents. Eur J Pharmacol 271:167-177
39. 1A receptor involvement in yawning and penile erections induced by apomorphine, physostigmine and mCPP in rats. Psychopharmacology 120:376-383
40. 1A receptor agonist 8-OH-DPAT in rats. Pharmacol Biochem Behav 33:329-334
41. 1A receptor binding sites in the rat brain - a quantitative autoradiographic study. J Neurochem 58:1338-1346
42. 1A receptor mRNA after irreversible inactivation with EEDQ. Mol Brain Res 38:233-242
43. Riblet LA, Taylor DP, Eison MS, Stanton HC (1982) Pharmacology and neurochemistry of buspirone. J Clin Psychiatry 12: 11-16
44. 2 receptor. Neuroreport 10:493-495
45. 7) activating cAMP formation. Proc Natl Acad Sci USA 90: 8547-8551
46. 3H]-8-OH-DPAT). Biochem Pharmacol 35:1943-1949
47. Tallarida RJ, Murray RB (1987) Manual of pharmacologic calculations. Springer, Berlin Heidelberg New York
48. 1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino)tetralin in the rat. Eur J Pharmacol 106:271-282
49. Tunnicliff G, Eison AS, Taylor DP (1991) Buspirone: mechanisms and clinical aspects. Academic Press, San Diego
50. Van Wijngaarden I, Tulp MTM, Soudijn W (1990) The concept of selectivity in 5-HT receptor research. Eur J Pharmacol 188: 301-312
51. Winer BJ (1971) Statistical principles in experimental design, 2nd edn. McGraw-Hill, New York
52. Zernig G, Issaevitch T (1995) Software for the calculation of agonist efficacy and apparent in vivo affinity by simultaneous analysis of several dose-response curves. Wolfram Research, Champaign, IL
53. Zernig G, Issaevitch T, Woods JH (1996) Calculation of agonist efficacy, apparent affinity, and receptor population changes after administration of insurmountable antagonists: comparison of different analytical approaches. J Pharmacol Toxicol Methods 35:223-237